Gangadhara Sailaja, Kwon Young-Man, Jeeva Subbiah, Quan Fu-Shi, Wang Baozhong, Moss Bernard, Compans Richard W, Amara Rama Rao, Jabbar M Abdul, Kang Sang-Moo
Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA.
Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Vaccines (Basel). 2017 Dec 19;5(4):52. doi: 10.3390/vaccines5040052.
Heterologous prime boost with DNA and recombinant modified vaccinia virus Ankara (rMVA) vaccines is considered as a promising vaccination approach against human immunodeficiency virus (HIV-1). To further enhance the efficacy of DNA-rMVA vaccination, we investigated humoral and cellular immune responses in mice after three sequential immunizations with DNA, a combination of DNA and virus-like particles (VLP), and rMVA expressing HIV-1 89.6 gp120 envelope proteins (Env). DNA prime and boost with a combination of VLP and DNA vaccines followed by an rMVA boost induced over a 100-fold increase in Env-specific IgG antibody titers compared to three sequential immunizations with DNA and rMVA. Cellular immune responses were induced by VLP-DNA and rMVA vaccinations at high levels in CD8 T cells, CD4 T cells, and peripheral blood mononuclear cells secreting interferon (IFN)-γ, and spleen cells producing interleukin (IL)-2, 4, 5 cytokines. This study suggests that a DNA and VLP combination vaccine with MVA is a promising strategy in enhancing the efficacy of DNA-rMVA vaccination against HIV-1.
用DNA疫苗和重组改良安卡拉痘苗病毒(rMVA)疫苗进行异源初免-加强免疫被认为是一种有前景的抗人类免疫缺陷病毒(HIV-1)疫苗接种方法。为进一步提高DNA-rMVA疫苗接种的效力,我们在小鼠中依次用DNA、DNA与病毒样颗粒(VLP)的组合以及表达HIV-1 89.6 gp120包膜蛋白(Env)的rMVA进行三次免疫后,研究了体液免疫和细胞免疫反应。与用DNA和rMVA进行三次连续免疫相比,先用DNA初免,再用VLP与DNA疫苗的组合进行加强免疫,随后用rMVA加强免疫,可使Env特异性IgG抗体滴度提高100倍以上。VLP-DNA和rMVA疫苗接种在分泌干扰素(IFN)-γ的CD8 T细胞、CD4 T细胞和外周血单个核细胞以及产生白细胞介素(IL)-2、4、5细胞因子的脾细胞中高水平诱导细胞免疫反应。本研究表明,DNA与VLP的联合疫苗以及MVA是提高DNA-rMVA疫苗抗HIV-1效力的一种有前景的策略。